These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 15714219)

  • 1. Gene therapy: the 'pro-sense' approach to Duchenne muscular dystrophy.
    van Deutekom JC
    Eur J Hum Genet; 2005 May; 13(5):518-9. PubMed ID: 15714219
    [No Abstract]   [Full Text] [Related]  

  • 2. Splicing intervention for Duchenne muscular dystrophy.
    McClorey G; Fletcher S; Wilton S
    Curr Opin Pharmacol; 2005 Oct; 5(5):529-34. PubMed ID: 16085461
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetics. Hopping to a better protein.
    Pennisi E
    Science; 2008 Dec; 322(5907):1454-5. PubMed ID: 19056949
    [No Abstract]   [Full Text] [Related]  

  • 4. Antisense therapy to ameliorate DMD.
    Ramsay M
    Trends Mol Med; 2001 Mar; 7(3):101. PubMed ID: 11286770
    [No Abstract]   [Full Text] [Related]  

  • 5. Exon skipping with morpholino oligomers: new treatment option for cardiomyopathy in Duchenne muscular dystrophy?
    Bauer R; Katus HA; Müller OJ
    Cardiovasc Res; 2010 Feb; 85(3):409-10. PubMed ID: 20008475
    [No Abstract]   [Full Text] [Related]  

  • 6. Myodys, a full-length dystrophin plasmid vector for Duchenne and Becker muscular dystrophy gene therapy.
    Duan D
    Curr Opin Mol Ther; 2008 Feb; 10(1):86-94. PubMed ID: 18228186
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Advances in Duchenne muscular dystrophy gene therapy.
    van Deutekom JC; van Ommen GJ
    Nat Rev Genet; 2003 Oct; 4(10):774-83. PubMed ID: 14526374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Molecular therapy for duchenne muscular dystrophy].
    Takeshima Y
    Nihon Rinsho; 2005 Dec; 63 Suppl 12():626-31. PubMed ID: 16416864
    [No Abstract]   [Full Text] [Related]  

  • 9. Engineering U7snRNA gene to reframe transcripts.
    Goyenvalle A
    Methods Mol Biol; 2012; 867():259-71. PubMed ID: 22454067
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
    Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
    J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intraperitoneal administration of phosphorothioate antisense oligodeoxynucleotide against splicing enhancer sequence induced exon skipping in dystrophin mRNA expressed in mdx skeletal muscle.
    Takeshima Y; Yagi M; Wada H; Matsuo M
    Brain Dev; 2005 Oct; 27(7):488-93. PubMed ID: 16198206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A highly functional mini-dystrophin/GFP fusion gene for cell and gene therapy studies of Duchenne muscular dystrophy.
    Li S; Kimura E; Ng R; Fall BM; Meuse L; Reyes M; Faulkner JA; Chamberlain JS
    Hum Mol Genet; 2006 May; 15(10):1610-22. PubMed ID: 16595609
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Modification of pre-mRNA processing: application to dystrophin expression.
    Wilton SD; Fletcher S
    Curr Opin Mol Ther; 2006 Apr; 8(2):130-5. PubMed ID: 16610765
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
    Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
    BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The future of Duchenne muscular dystrophy gene therapy: shrinking the dystrophin gene.
    Roberts M; Dickson G
    Curr Opin Mol Ther; 2002 Aug; 4(4):343-8. PubMed ID: 12222872
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficient and fast functional screening of microdystrophin constructs in vivo and in vitro for therapy of duchenne muscular dystrophy.
    Jørgensen LH; Larochelle N; Orlopp K; Dunant P; Dudley RW; Stucka R; Thirion C; Walter MC; Laval SH; Lochmüller H
    Hum Gene Ther; 2009 Jun; 20(6):641-50. PubMed ID: 19239382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induced dystrophin exon skipping in human muscle explants.
    McClorey G; Fall AM; Moulton HM; Iversen PL; Rasko JE; Ryan M; Fletcher S; Wilton SD
    Neuromuscul Disord; 2006 Oct; 16(9-10):583-90. PubMed ID: 16919955
    [TBL] [Abstract][Full Text] [Related]  

  • 18. U1 snRNA as an effective vector for stable expression of antisense molecules and for the inhibition of the splicing reaction.
    Martone J; De Angelis FG; Bozzoni I
    Methods Mol Biol; 2012; 867():239-57. PubMed ID: 22454066
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Design of trans-splicing adeno-associated viral vectors for Duchenne muscular dystrophy gene therapy.
    Lai Y; Li D; Yue Y; Duan D
    Methods Mol Biol; 2008; 433():259-75. PubMed ID: 18679629
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
    Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
    Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.